Cargando…

BIOL-18. NEWLY DEVELOPED REPLICATION REPAIR DEFICIENT (RRD) MOUSE MODELS PROVIDE INSIGHTS INTO MEDULLOBLASTOMA/GLIOMAGENESIS AND RESPONSE TO IMMUNOTHERAPY

Replication Repair Deficiency (RRD), caused by germline monoallelic (Lynch Syndrome) or biallelic (Constitutional Mismatch Repair Deficiency, CMMRD) mutations in MMR genes, is present in 5-10% of glioblastomas in children, adolescents, and young adults. RRD glioblastomas are chemoradiation-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aamir, Zoya, Galati, Melissa, Gattoni, Emma, Crump, Owen, Nunes, Nuno M, Das, Anirban, Fernandez, Nicholas R, Wong, Angel K Q, Fortin, Jerome, Stengs, Lucie, Bianchi, Vanessa, Edwards, Melissa, Negm, Logine, Chung, Jiil, Malkin, David, Egan, Sean, Hawkins, Cynthia, Tabori, Uri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Basic Biology/Stem Cells/Models - BIOL
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259929/ http://dx.doi.org/10.1093/neuonc/noad073.037

Ejemplares similares

MDB-12. TRANS-SPECIES ANALYSIS OF REPLICATION-REPAIR DEFICIENT (RRD) MEDULLOBLASTOMA AND RESPONSE TO IMMUNE-CHECKPOINT INHIBITION: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

BIOL-06. UNDERSTANDING OLIGODENDROCYTE PROGENITOR CELL CONTRIBUTION TO GLIOMAGENESIS USING A NOVEL PHARMACOGENETIC ABLATION TOOL
por: Xing, Lulu, et al.
Publicado: (2023)

BIOL-08. RADIATION DRIVES METASTASIS IN MEDULLOBLASTOMA THROUGH AN INFLAMMATORY PROCESS
por: Nor, Carolina, et al.
Publicado: (2023)

BIOL-12. ENHANCING IMMUNE-MEDIATED TUMOR CONTROL IN MURINE MODELS OF GROUP 3 MEDULLOBLASTOMA
por: Abbas, Zahra, et al.
Publicado: (2023)

BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA
por: Llaguno, Sheila Alcantara, et al.
Publicado: (2023)

HGG-26. GENOMIC AND IMMUNE ANALYSIS OF PRIMARY REPLICATION-REPAIR DEFICIENT (RRD) GLIOMAS REVEALS THREE SUBGROUPS WITH DISTINCT DRIVERS AND RESPONSE TO IMMUNOTHERAPY: AN IRRDC REPORT
por: Fernandez, Nicholas R, et al.
Publicado: (2023)

BIOL-02. MODELING BRAIN TUMORS IN VIVO AND WITH HUMAN ORGANOIDS
por: Tiberi, Luca
Publicado: (2023)

BIOL-01. GENERATION AND MULTI-OMICS CHARACTERIZATION OF 203 PEDIATRIC CNS TUMOUR MODELS REVEALS NEW THERAPEUTIC VULNERABILITIES
por: Sun, Claire, et al.
Publicado: (2023)

BIOL-17. DISSECTING THE EXPRESSION AND FUNCTION OF ANGIOPOIETIN-1 IN PEDIATRIC BRAIN TUMORS
por: Langhnoja, Jaldeep, et al.
Publicado: (2023)

BIOL-19. DIFFUSE MIDLINE GLIOMA CEREBRAL ORGANOID MODEL AND MULTIOMICS CHARACTERIZATION
por: Damodharan, Sudarshawn, et al.
Publicado: (2023)

BIOL-11. PRECLINICAL MODELLING OF PEDIATRIC BRAIN TUMORS USING ORGANOID TECHNOLOGY
por: Roosen, Mieke, et al.
Publicado: (2023)

BIOL-04. FROM MSWI/SNF’S ROLES IN PROTEIN SYNTHESIS TO NEW THERAPEUTIC OPPORTUNITIES
por: Van Rechem, Capucine
Publicado: (2023)

BIOL-03. NOVEL GENETICALLY ENGINEERED MOUSE MODEL FOR CHOROID PLEXUS CARCINOMA MIMICS HUMAN DISEASE
por: Duarte, Matilde de Almeida, et al.
Publicado: (2023)

BIOL-20. BIOPROCESSING OF SURGICAL PEDIATRIC BRAIN TUMOR SPECIMENS FOR GENOME-GUIDED PERSONALIZED DRUG TESTING
por: Nasajpour, Emon, et al.
Publicado: (2023)

BIOL-21. PATIENT-DERIVED, THREE-DIMENSIONAL ORGANOID PLATFORM FOR PEDIATRIC BRAIN TUMOR MODELING AND THERAPEUTIC TESTING
por: Beale, David, et al.
Publicado: (2023)

BIOL-13. DEPLOYING NEW MODELS OF NF-1 MUTANT LOW GRADE GLIOMA TO ACCELERATE THERAPEUTIC DEVELOPMENT
por: Alaali, Lujain, et al.
Publicado: (2023)

BIOL-10. MOUSE MODELING OF PEDIATRIC MYCN GLIOMA REVEALS INTRATUMORAL HETEROGENEITY INCLUDING NEURONAL AND OLIGODENDROGLIAL LINEAGE SIGNATURES
por: Schoof, Melanie, et al.
Publicado: (2023)

BIOL-05. IDENTIFICATION AND VALIDATION OF PA2G4 AS A POTENTIAL THERAPEUTIC TARGET IN PEDIATRIC DIFFUSE GLIOMAS
por: Sirhan, Zaid, et al.
Publicado: (2023)

BIOL-24. USING NEEDLE WASH SPECIMEN AFTER STEREOTACTIC BIOPSY TO DEVELOP PDOX MODELS OF DIPG AND DIFFUSE MIDLINE GLIOMAS
por: Abdallah, Aalaa, et al.
Publicado: (2023)

BIOL-15. PATIENT-DERIVED XENOGRAFTS OF MATCHED PRIMARY-RECURRENT PEDIATRIC BRAIN TUMORS AS A RESOURCE FOR IDENTIFYING THERAPY RESISTANCE PROFILES
por: Zhao, Miao, et al.
Publicado: (2023)

BIOL-16. OBESOGENIC DIET EXPOSURE INCREASES NF1-OPTIC PATHWAY GLIOMA FORMATION IN PART THROUGH EFFECTS ON THE CELL OF ORIGIN
por: Chan, Ambrose, et al.
Publicado: (2023)

BIOL-14. FROM NON-MALIGNANT TO MALIGNANT: GENERATING AND TARGETING DIFFUSE MIDLINE GLIOMA IN A NOVEL HUMAN PONTINE ORGANOID MODEL
por: Bessler, Nils, et al.
Publicado: (2023)

BIOL-07. DISTINCTIVE FEATURES OF HIGH-GRADE GLIOMA MOUSE MODELS REVEALED BY SINGLE-NUCLEUS RNA-SEQUENCING GUIDE PRE-CLINICAL MODEL SELECTION
por: Ernst, Kati, et al.
Publicado: (2023)

BIOL-22. CHILDREN’S BRAIN TUMOR NETWORK PRECLINICAL TUMOR MODELS DEVELOPMENT AND SHARING PLATFORM: COLLABORATIVE MODEL EMPOWERING PEDIATRIC BRAIN TUMOR DISCOVERY AND GLOBAL RESEARCH
por: Hollawell, Madison, et al.
Publicado: (2023)

BIOL-09. PROTEOMIC ANALYSES REVEAL THAT CO-CULTURE OF DIFFUSE INTRINSIC PONTINE GLIOME (DIPG) WITH CORTICAL ORGANOIDS ALTERS CELL ADHESION, DNA SYNTHESIS AND REPLICATION, AND DENDRITIC GROWTH SIGNALLING
por: Prior, Victoria, et al.
Publicado: (2023)

IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

MDB-15. CLINICAL CHARACTERISTICS AND OUTCOME OF CHILDHOOD LI-FRAUMENI SYNDROME MEDULLOBLASTOMA PATIENTS
por: Kolodziejczak, Anna, et al.
Publicado: (2023)

HGG-27. THE IMPACT OF MISMATCH REPAIR DEFICIENCY ON GLIOMAS IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS; A REPORT FROM THE IRRDC AND THE GLIOMA TASK FORCE
por: Negm, Logine, et al.
Publicado: (2023)

PAEDIATRIC-01 SURGICAL OUTCOME OF MEDULLOBLASTOMA IN ETHIOPIA
por: Akililu, Yemisirach Bizuneh, et al.
Publicado: (2023)

MDB-42. UNCOVERING DYNAMIC CHANGES IN MEDULLOBLASTOMA ASSOCIATED VASCULATURE IN ZEBRAFISH
por: Morris, Elysse, et al.
Publicado: (2023)

MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023)

MDB-28. DEEP LEARNING-BASED PERSONALIZED SURVIVAL PREDICTION FOR MEDULLOBLASTOMA
por: Stefan, Sabina, et al.
Publicado: (2023)

MDB-40. TRANSCRIPTOME-BASED DRUG REPURPOSING IN GROUP 3 MEDULLOBLASTOMA
por: Doss, David, et al.
Publicado: (2023)

MDB-23. ELP1 GERMLINE DEFICIENCY SENSITIZES THE GRANULE NEURON LINEAGE TO SHH MEDULLOBLASTOMA AND EXPOSES NOVEL THERAPEUTIC VULNERABILITIES
por: Garcia-Lopez, Jesus, et al.
Publicado: (2023)

MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS
por: Jermakowicz, Anna, et al.
Publicado: (2023)

MDB-41. TARGETING EPIGENETIC REGULATORS TO INHIBIT GROUP 3 MEDULLOBLASTOMA MIGRATION
por: Jangde, Nitish, et al.
Publicado: (2023)

MDB-01. ELUCIDATING THE ROLE OF THE BAIAP2-CDC42 INTERACTION MEDULLOBLASTOMA
por: Ruiz, Luz, et al.
Publicado: (2023)

MDB-29. MEDULLOBLASTOMA SUBGROUP-SPECIFIC CHROMATIN STATES REVEAL NOVEL THERAPEUTIC VULNERABILITIES
por: Tao, Ran, et al.
Publicado: (2023)

MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA
por: Caisova, Veronika, et al.
Publicado: (2023)

MDB-35. RECURRENT MEDULLOBLASTOMA A RARE COMPLETE RESPONSE IN EXTRA NEURAL DISEASE
por: Schwartz, Jonathan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2346m3604q04ouq5jtgk5a2ji6